Tetanus, Reduced Diphtheria and Acellular Pertussis & Inactivated Poliovirus (Tdap-IPV) Vaccine

[SVL] Tetanus, Reduced Diphtheria and Acellular Pertussis & Inactivated Poliovirus (Tdap-IPV) (Adacel-Polio) Injection, Diphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mL + Pertussis Toxoid Vaccine 2.5 micrograms/0.5 mL + Filamentous Haemagglutinin 5 micrograms/0.5 mL + Pertactin 3 micrograms/0.5 mL + Fimbriae Type-2 & Type-3 5 micrograms/0.5 mL + Poliovirus Vaccine (inactivated) Type-1 40 D-antigen unit/0.5 mL + Poliovirus Vaccine (inactivated) Type-2 8 D-antigen unit/0.5 mL + Poliovirus Vaccine (inactivated) Type-3 32 D-antigen unit/0.5 mL

1. National Childhood Immunisation Schedule (NCIS)

[SVL] Tetanus, Reduced Diphtheria and Acellular Pertussis & Inactivated Poliovirus (Tdap-IPV) (Boostrix Polio) Injection, Diphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mL + Pertussis Toxoid Vaccine 8 micrograms/0.5 mL + Filamentous Haemagglutinin 8 micrograms/0.5 mL + Pertactin 2.5 micrograms/0.5 mL + Poliovirus Vaccine (inactivated) Type-1 40 D-antigen unit/0.5 mL + Poliovirus Vaccine (inactivated) Type-2 8 D-antigen unit/0.5 mL + Poliovirus Vaccine (inactivated) Type-3 32 D-antigen unit/0.5 mL

1. National Childhood Immunisation Schedule (NCIS)

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

Not Applicable

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration